PriceTargets.com logo

Aligos Therapeutics - ALGS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $50.00
  • Forecasted Upside: 395.54%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.09 As of 12/4/2025 05:00 PM ET
▲ +0.22 (2.23%)

This chart shows the closing price for ALGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aligos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALGS

Analyst Price Target is $50.00
▲ +395.54% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aligos Therapeutics in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 395.54% upside from the last price of $10.09.

This chart shows the closing price for ALGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Aligos Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/18/2025HC WainwrightInitiated CoverageBuy$50.00
3/31/2025HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
3/11/2025HC WainwrightLower TargetBuy ➝ Buy$75.00 ➝ $70.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
10/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
9/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
8/19/2024HC WainwrightInitiated CoverageBuy$75.00
1/16/2023Piper SandlerBoost Target$75.00 ➝ $175.00
1/6/2023Piper SandlerUpgradeNeutral ➝ Overweight$50.00 ➝ $75.00
1/6/2023Jefferies Financial GroupUpgradeHold ➝ Buy$62.50 ➝ $75.00
11/3/2022Leerink PartnersLower TargetMarket Perform$75.00 ➝ $50.00
8/8/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
6/8/2022Cantor FitzgeraldReiterated RatingOverweight
5/5/2022Leerink PartnersDowngradeOutperform ➝ Market Perform
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/23/2022Leerink PartnersLower TargetOutperform$275.00 ➝ $175.00
3/23/2022Piper SandlerDowngradeOverweight ➝ Neutral$375.00 ➝ $100.00
3/11/2022Piper SandlerLower TargetOverweight$1,175.00 ➝ $375.00
3/11/2022Leerink PartnersBoost TargetOutperform$250.00 ➝ $275.00
2/16/2022Leerink PartnersLower TargetOutperform$375.00 ➝ $250.00
1/7/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$750.00 ➝ $300.00
1/7/2022Leerink PartnersLower TargetOutperform$725.00 ➝ $375.00
1/6/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$500.00 ➝ $125.00
9/9/2021Leerink PartnersInitiated CoverageOutperform$725.00
5/17/2021Piper SandlerInitiated CoverageOverweight$1,175.00 ➝ $875.00
4/1/2021Jefferies Financial GroupReiterated RatingBuy$1,050.00
3/24/2021Piper SandlerBoost TargetOverweight$875.00 ➝ $1,000.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aligos Therapeutics logo
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $10.09
Low: $9.80
High: $10.45

50 Day Range

MA: $9.00
Low: $6.07
High: $10.51

52 Week Range

Now: $10.09
Low: $3.76
High: $46.80

Volume

69,290 shs

Average Volume

78,991 shs

Market Capitalization

$62.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Aligos Therapeutics?

The following Wall Street analysts have issued reports on Aligos Therapeutics in the last twelve months: HC Wainwright, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ALGS.

What is the current price target for Aligos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aligos Therapeutics in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 395.5%. HC Wainwright has the highest price target set, predicting ALGS will reach $50.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $50.00 for Aligos Therapeutics in the next year.
View the latest price targets for ALGS.

What is the current consensus analyst rating for Aligos Therapeutics?

Aligos Therapeutics currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALGS, but not buy more shares or sell existing shares.
View the latest ratings for ALGS.

What other companies compete with Aligos Therapeutics?

Other companies that are similar to Aligos Therapeutics include GENFIT, Editas Medicine, Sagimet Biosciences, Tenaya Therapeutics and Forte Biosciences. Learn More about companies similar to Aligos Therapeutics.

How do I contact Aligos Therapeutics' investor relations team?

The company's listed phone number is 800-466-6059 and its investor relations email address is [email protected]. The official website for Aligos Therapeutics is www.aligos.com. Learn More about contacing Aligos Therapeutics investor relations.